These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 29960044

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Neutralizing antibodies to interferon beta-1a and interferon beta-1b in MS patients are cross-reactive.
    Khan OA, Dhib-Jalbut SS.
    Neurology; 1998 Dec; 51(6):1698-702. PubMed ID: 9855525
    [Abstract] [Full Text] [Related]

  • 3. Determination of interferon beta neutralizing antibodies in multiple sclerosis: improvement of clinical sensitivity of a cytopathic effect assay.
    Massart C, Gibassier J, de Seze J, Debouverie M, Moreau T, Pelletier J, Vermersch P, Edan G.
    Clin Chim Acta; 2008 May; 391(1-2):98-101. PubMed ID: 18249193
    [Abstract] [Full Text] [Related]

  • 4. Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta.
    Bertolotto A, Sala A, Caldano M, Capobianco M, Malucchi S, Marnetto F, Gilli F.
    J Immunol Methods; 2007 Apr 10; 321(1-2):19-31. PubMed ID: 17335844
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNbeta in multiple sclerosis patients.
    Lam R, Farrell R, Aziz T, Gibbs E, Giovannoni G, Grossberg S, Oger J.
    J Immunol Methods; 2008 Jul 31; 336(2):113-8. PubMed ID: 18511063
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Neutralizing antibodies to interferon beta in multiple sclerosis: analytical evaluation for validation of a cytopathic effect assay.
    Massart C, Gibassier J, Oger J, Le Page E, Edan G.
    Clin Chim Acta; 2007 Feb 31; 377(1-2):185-91. PubMed ID: 17123498
    [Abstract] [Full Text] [Related]

  • 9. Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study.
    Pachner AR, Warth JD, Pace A, Goelz S, INSIGHT investigators.
    Neurology; 2009 Nov 03; 73(18):1493-500. PubMed ID: 19884577
    [Abstract] [Full Text] [Related]

  • 10. Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis.
    Grossberg SE, Oger J, Grossberg LD, Gehchan A, Klein JP.
    J Interferon Cytokine Res; 2011 Mar 03; 31(3):337-44. PubMed ID: 21226608
    [Abstract] [Full Text] [Related]

  • 11. Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice.
    Jungedal R, Lundkvist M, Engdahl E, Ramanujam R, Westerlind H, Sominanda A, Hillert J, Fogdell-Hahn A.
    Mult Scler; 2012 Dec 03; 18(12):1775-81. PubMed ID: 22551640
    [Abstract] [Full Text] [Related]

  • 12. Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis.
    Herndon RM, Rudick RA, Munschauer FE, Mass MK, Salazar AM, Coats ME, Labutta R, Richert JR, Cohan SL, Genain C, Goodkin D, Toal M, Riester K.
    Mult Scler; 2005 Aug 03; 11(4):409-19. PubMed ID: 16042223
    [Abstract] [Full Text] [Related]

  • 13. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory.
    Bertolotto A, Malucchi S, Sala A, Orefice G, Carrieri PB, Capobianco M, Milano E, Melis F, Giordana MT.
    J Neurol Neurosurg Psychiatry; 2002 Aug 03; 73(2):148-53. PubMed ID: 12122172
    [Abstract] [Full Text] [Related]

  • 14. Neutralizing antibodies to interferon (IFN) alpha-2a and IFN beta-1a or IFN beta-1b in MS are not cross-reactive.
    Myhr KM, Ross C, Nyland HI, Bendtzen K, Vedeler CA.
    Neurology; 2000 Nov 28; 55(10):1569-72. PubMed ID: 11094118
    [Abstract] [Full Text] [Related]

  • 15. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients.
    Bertolotto A, Gilli F, Sala A, Capobianco M, Malucchi S, Milano E, Melis F, Marnetto F, Lindberg RL, Bottero R, Di Sapio A, Giordana MT.
    Neurology; 2003 Feb 25; 60(4):634-9. PubMed ID: 12601105
    [Abstract] [Full Text] [Related]

  • 16. MxA mRNA decrease preceding NAb detection in IFNβ-treated MS patients.
    Libertinova J, Meluzinova E, Matoska V, Zajac M, Kovarova I, Havrdova E, Horakova D, Tomek A, Marusic P, Bojar M.
    Brain Behav; 2017 Mar 25; 7(3):e00644. PubMed ID: 28293479
    [Abstract] [Full Text] [Related]

  • 17. One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients.
    Malucchi S, Gilli F, Caldano M, Sala A, Capobianco M, di Sapio A, Granieri L, Bertolotto A.
    J Neurol; 2011 May 25; 258(5):895-903. PubMed ID: 21153733
    [Abstract] [Full Text] [Related]

  • 18. Measurement of neutralizing antibodies to interferon beta in patients with multiple sclerosis.
    Deisenhammer F, Schellekens H, Bertolotto A.
    J Neurol; 2004 Jun 25; 251 Suppl 2():II31-9. PubMed ID: 15264110
    [Abstract] [Full Text] [Related]

  • 19. Incorporation of an interferon-β neutralizing antibody assay into routine clinical practice.
    Farrell RA, Espasandin M, Lakdawala N, Creeke PI, Worthington V, Giovannoni G.
    Mult Scler; 2011 Nov 25; 17(11):1333-40. PubMed ID: 21685230
    [Abstract] [Full Text] [Related]

  • 20. Antibodies to interferon beta in patients with multiple sclerosis receiving CinnoVex, rebif, and betaferon.
    Zare N, Zarkesh-Esfahani SH, Gharagozloo M, Shaygannejad V.
    J Korean Med Sci; 2013 Dec 25; 28(12):1801-6. PubMed ID: 24339712
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.